Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorodopa F 18
- Development stage
- Approved
- Lead developer
- The Feinstein Institutes for Medical Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
Fluorodopa F 18 is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging. It is an amino acid analog of fluorodopa labeled with the positron-emitting isotope fluorine F 18. The drug is designed to cross the blood-brain barrier and be taken up by dopaminergic nerve terminals in the striatum. Once inside, it is decarboxylated by amino acid decarboxylase to fluorodopamine, which is then stored in presynaptic vesicles. The radioactive decay of Fluorine-18 allows for the visualization of these dopaminergic pathways via PET scans, aiding in the evaluation and diagnosis of adult patients with suspected Parkinsonian syndromes and other neurological conditions. It also has potential as a tumor tracer for various cancers.
- Brand names
- Fluorodopa F18
- Other names
- fluorodeoxyphenylalanine 18F-DOPAfluorodeoxyphenylalanine18F-DOPAfluorodeoxyphenylalanine-18F-DOPA
02
Targets
SLC7A5 (Large neutral amino acid transporter small subunit 1)VMAT2 (Vesicular monoamine transporter 2)DDC (Aromatic L-amino acid decarboxylase)SERPINA1 (Alpha-1-antitrypsin)
Beyond the preview
Go deeper on Fluorodopa F 18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fluorodopa F 18.